UNSPSC 51332808: Ciclofenazine or cyclophenazine

This classification denotes a serotonin antagonist and dopamine antagonist, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier OH4ZJ36RB2. European Medicines Agency schedules Ciclofenazine in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06241MIG. Ciclofenazine generally arises in the molecular formula C23H26F3N3S.

The term CICLOFENAZINE is an International Non-Proprietary Name or INN (see WHO INN reference publication, Volume 22, no. 10, 1968, list 8.) CICLOFENAZINE is scheduled in the U.S. International Trade Commission's Harmonized Tariff System (HTS) Pharmaceutical Appendix. Ciclofenazine or cyclophenazine bears US NLM identifiers UMLS ID C2825451 and NCI Concept Code C81097. SMILES: C1CC1N2CCN(CC2)CCCN3C4=CC=CC=C4SC5=C3C=C(C=C5)C(F)(F)F.

UNSPSC 51332808 Ciclofenazine or cyclophenazine, a Commodity code, shows no recent state and local procurement activity that aligns with its nominal scope. The most recent opportunities posted under this code—a Seminole County, Florida naloxone and drug deactivation systems procurement (IFB, due July 26, 2023), a Texas Health and Human Services Commission Request for Information on direct-to-manufacturer prescription programs (RFI, due April 3, 2026), and a Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) generic multi-source pharmaceuticals and OTC products contract (RFP, due March 26, 2026)—are tangentially health-related but do not involve ciclofenazine or cyclophenazine procurement. The Seminole County opportunity solicits naloxone and drug deactivation systems for community health support; the Texas RFI seeks vendor capabilities for pharmacy benefit management innovation; and the MMCAP RFP establishes multi-state contracts for generic pharmaceuticals and OTC products through authorized wholesalers. None of these solicitations specifies ciclofenazine or cyclophenazine as a product line or active pharmaceutical ingredient.

The code's recent activity does not support a meaningful characterization of issuing-body mix, geographic concentration, or representative ciclofenazine procurement. Buyers posting under this code span county health departments, state health agencies, and multistate cooperative purchasing alliances, but their actual purchasing focus lies in opioid-antagonist medications, pharmacy benefit program design, and broad-spectrum generic pharmaceutical distribution—not the specific compound this code nominates. Business development professionals should verify whether ciclofenazine or cyclophenazine appears in state or local agency formularies, contract catalogs, or buying guides before targeting procurement opportunities nominally tagged to this code; the current record suggests the code is either misapplied at posting or reflects minimal state and local demand for this pharmaceutical.